tiprankstipranks
Analyst Profile
Followed by 368 other investors
.
Jonathan Aschoff

Jonathan Aschoff

Roth Capital
Wall Street Analyst
Ranked #7,875 out of 8,047 Analysts on TipRanks (#20,899 out of 21,521 overall experts)

Success Rate

35%
138 out of 391 Profitable Transactions

Average Return

-7.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Jonathan Aschoff's ratings since 2012 and opened each position for the duration of 1 Year:
35.29% of your transactions would have been profitable with an average return of -7.7%

Stock Rating Distribution

478Ratings
88.49% Buy
5.86% Sell
5.65% Hold
Distribution of Jonathan Aschoff's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Seelos Therapeutics, Inc.
(SEEL)
Rating Type:Buy
Dates:Sep 09, 2020 - May 17, 2021
Gain:523.80%
The most profitable rating made by Jonathan Aschoff

Jonathan Aschoff's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
SGYPQ
Synergy Pharmaceuticals Inc
Mar 29, 2012
Buy
Initiated
100%
+50.90%
1
Halozyme
Apr 16, 2012
Buy
Reiterated
$11.00
(-74.50% Downside)
0%
-30.60%
2
RDEA
Ardea Biosciences
Apr 23, 2012
Hold
Downgraded
0.00%
1
ONXX
Onyx Pharma
Jun 21, 2012
Buy
Upgraded
100%
+28.30%
1
Assembly Biosciences
Jun 29, 2012
Buy
Reiterated
0%
-79.30%
2
Celsion
Jan 17, 2013
Sell
Downgraded
$1.00
(-61.24% Downside)
100%
+87.90%
1
United Therapeutics
Feb 26, 2013
Hold
Downgraded
0.00%
1
ARIA
Ariad
Oct 09, 2013
Hold
Downgraded
0%
-20.80%
2
DNDNQ
Dendreon Corp
Mar 03, 2014
Sell
Reiterated
75%
+37.24%
8
AUXL
Auxilium
Sep 10, 2014
Sell
Initiated
0%
-67.35%
2
List of latest recommendations made by Jonathan Aschoff. Click to expand and see Jonathan Aschoff's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More